Goztepe Prof.Dr. Suleyman Yalcin City Hospital; Clinical Oncology
Kadikoy, Turkey
Hospital in Istanbul
Eğitim, Göztepe Araştırma Hst., 34722 Kadıköy/İstanbul
About Goztepe Prof.Dr. Suleyman Yalcin City Hospital; Clinical Oncology
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Hoffmann-La Roche
6
Pfizer
2
Clinical Trials at Goztepe Prof.Dr. Suleyman Yalcin City Hospital; Clinical Oncology
During the past decade, Goztepe Prof.Dr. Suleyman Yalcin City Hospital; Clinical Oncology conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 2 clinical trials were completed, i.e. on
average, 28.6% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 2 clinical trials were completed. i.e. 66.7%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
Long-Term Safety Study Of Tofacitinib In Patients With Juvenile Idiopathic Arthritis
2013-03-18
2025-11-08
Recruiting
340
Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
2016-06-30
2023-06-30
Active, not recruiting
1,214
A Safety, Efficacy And Pharmacokinetics Study Of Tofacitinib In Pediatric Patients With sJIA
2018-05-10
2024-03-26
Recruiting
100
A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)
2017-08-25
2023-01-17
Completed
653
Basket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors
2018-02-19
2021-12-30
Terminated
256
A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer
2020-03-04
2025-02-21
Recruiting
660
A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy
2020-09-28
2025-06-27
Recruiting
750
A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer
2021-11-18
2026-03-06
Recruiting
690
Clinical Trials Sponsors and Collaborators
In terms of collaborators to trials, out of the total clinical trials conducted in "Goztepe Prof.Dr. Suleyman Yalcin City Hospital; Clinical Oncology"
#1 collaborator was "Jazz Pharmaceuticals" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were
collaborators in the rest 1 trials.
Clinical Trials Conditions at Goztepe Prof.Dr. Suleyman Yalcin City Hospital; Clinical Oncology
According to Clinical.Site data, the most researched conditions in "Goztepe Prof.Dr. Suleyman Yalcin City Hospital; Clinical Oncology" are
"Advanced/Metastatic Head and Neck, Oesophageal and Cervical Cancers" (1 trials), "Arthritis Juvenile Idiopathic" (1 trials), "Esophageal Squamous Cell Carcinoma" (1 trials), "Juvenile Idiopathic Arthritis" (1 trials) and "Non-Small Cell Lung Cancer" (1 trials). Many other conditions were trialed in "Goztepe Prof.Dr. Suleyman Yalcin City Hospital; Clinical Oncology" in a lesser frequency.
Clinical Trials Intervention Types at Goztepe Prof.Dr. Suleyman Yalcin City Hospital; Clinical Oncology
Most popular intervention types in "Goztepe Prof.Dr. Suleyman Yalcin City Hospital; Clinical Oncology" are "Drug" (8 trials) and "Other" (1 trials). Other intervention types were less common.
The name of intervention was led by "Atezolizumab" (4 trials), "Carboplatin" (2 trials), "Gemcitabine" (2 trials), "Tiragolumab" (2 trials) and "Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody" (1 trials). Other intervention names were less common.
Clinical Trials Genders at Goztepe Prof.Dr. Suleyman Yalcin City Hospital; Clinical Oncology
The vast majority of trials in "Goztepe Prof.Dr. Suleyman Yalcin City Hospital; Clinical Oncology" are
8 trials for "All" genders.
Clinical Trials Status at Goztepe Prof.Dr. Suleyman Yalcin City Hospital; Clinical Oncology
Currently, there are NaN active trials in "Goztepe Prof.Dr. Suleyman Yalcin City Hospital; Clinical Oncology".
undefined are not yet recruiting,
5 are recruiting,
1 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 1 completed trials in Goztepe Prof.Dr. Suleyman Yalcin City Hospital; Clinical Oncology,
undefined suspended trials,
and 1 terminated clinical trials to date.
Out of the total trials that were conducted in Goztepe Prof.Dr. Suleyman Yalcin City Hospital; Clinical Oncology, 0 "Phase 1"
clinical trials were conducted, 1 "Phase 2" clinical
trials and 7 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".